A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2002
11/28/2002	US20020177581 Novel anti-inflammatory androstane derivative
11/28/2002	US20020177577 Contact lens preservative solution
11/28/2002	US20020177576 Nucleotide compounds that block the bitter taste of oral compositions
11/28/2002	US20020177573 Ligand for bacterial toxins, which is capable of selective interaction with the beta-sheet-hinge-alpha-helix structure of the superantigens.
11/28/2002	US20020177562 Dissolving in an acidified solvent and spray-drying to form a powder suitable for oral inhalation to the lung
11/28/2002	US20020177545 Compositions and methods for treating gonadotrophin related illnesses
11/28/2002	US20020177522 Solid media
11/28/2002	US20020177226 Pharmaceutical dipeptide compositions and methods of use thereof: immunostimulants
11/28/2002	US20020176911 Includes xanthan gum which improves tolerance (e.g. less gastrointestinal symptoms such as emesis, stool patterns and gas)
11/28/2002	US20020176904 Antiprotozal composition
11/28/2002	US20020176894 For an azole antifungal or antibacterial drug; core and a drug emulsion layer containing the drug, an emulsifier, binder and absorbent aid such as citric acid; solubility, bioavailability
11/28/2002	US20020176892 Sterile gelled composition of a matrix containing an anionic "polymer" such as chondroitin sulfate blended with a nonionic polymer such as hydroxyethyl cellulose in given ratio; topically applying for pain relief from e.g. arthritis
11/28/2002	US20020176891 Topical gel delivery system
11/28/2002	US20020176890 Gellan gum tablet coating
11/28/2002	US20020176888 Oral dosage forms
11/28/2002	US20020176886 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
11/28/2002	US20020176882 Additive the improvement and/or stabilization of the keeping quality of microbially perishable products
11/28/2002	US20020176856 Administering an antibody to the mammal, that binds with a specified target epitope of an antigen, associated with a tumor or an infectious agent; having engineered glycosylation site in the constant region of the heavy chain antibodies
11/28/2002	US20020176849 Endomural therapy
11/28/2002	US20020176846 Storage stable powder compositions of interleukin-4 receptor
11/28/2002	US20020176842 A dosage form comprising an ionizable active ingredient and an unloaded ion exchange resin, coated with a permeable membrane; drug release and absorption depending on the conditions under which the membrane dissolves
11/28/2002	US20020176841 Pharmaceutical formulations for sustained release
11/28/2002	US20020176835 Crosslinked water-soluble or water-swellable copolymers based on acrylamidoalkylsulfonic acids and cyclic N-vinylcarboxamides
11/28/2002	US20020176832 Cosmetic or dermatological oil-in-water emulsions comprising up to 90% by weight water phase, up to 40% by weight lipid phase, up to 10% by weight polymer
11/28/2002	US20020176827 Carrier and composition comprising polybutene with molecular weight of 300-3000 and one or more cosmetic or therapeutic actives, releasably associated to carrier
11/28/2002	DE10141650C1 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
11/28/2002	DE10125599A1 Super-absorbent polymer powder for use in e.g. diapers, packaging and soil improvers, obtained by pre-swelling polycarboxy-polysaccharide in water and then drying and surface-crosslinking resulting hydrogel
11/28/2002	DE10123505A1 New immunoconjugate comprising egg yolk immunoglobulin Y, useful for treating e.g. inflammation or infection, is derived from specific pathogen-free hens
11/28/2002	DE10114134A1 Production of modified hydroxy-polymer for use in immobilisation of proteins comprises reacting a solution of hydroxy-polymer in polar aprotic solvent with carboxylic acid, azide reagent and organic base
11/28/2002	CA2641760A1 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
11/28/2002	CA2454551A1 Controlled release drug delivery device
11/28/2002	CA2448031A1 Method for stabilising of nucleic acids
11/28/2002	CA2448022A1 Compositions for protein delivery via the pulmonary route
11/28/2002	CA2447795A1 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
11/28/2002	CA2447793A1 Immunostimulatory oligodeoxynucleic molecules
11/28/2002	CA2447603A1 Granular preparations of gaboxadol
11/28/2002	CA2447236A1 Pulmonary administration of chemically modified insulin
11/28/2002	CA2447170A1 Emulsion and dispersion formulations and method
11/28/2002	CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	CA2443438A1 Cytotoxic cd44 antibody immunoconjugates
11/28/2002	CA2443437A1 Antibodies specific for cd44v6
11/28/2002	CA2443068A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel
11/28/2002	CA2441801A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	CA2349123A1 Anionic exchange polymer complexes of buspirone
11/27/2002	EP1260582A1 Conjugates of factor IX and a biocompatible polymer
11/27/2002	EP1260534A2 Blends of absorbable polyoxaesters
11/27/2002	EP1260511A1 Process for the preparation of 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)indole and method of manufacturing sertindole
11/27/2002	EP1260233A1 P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
11/27/2002	EP1260230A1 Preparations stabilized over long time
11/27/2002	EP1260220A1 Bubbling tablet, bubbling bath additive tablet, bubbling washing detergent tablet, bubbling tablet for oral administration, and processes for producing these
11/27/2002	EP1260219A2 Dip coating compositions containing cellulose ethers
11/27/2002	EP1260218A2 Dip coating compositions containing starch or dextrin
11/27/2002	EP1260217A2 Simethicone as weight gain enhancer for coating compositions
11/27/2002	EP1260216A1 Multi-layered pharmaceutical composition for both intraoral and oral administration
11/27/2002	EP1260215A1 Rapidly disintegrable tablet containing polyvinyl alcohol
11/27/2002	EP1259814A1 Bcmp-7 as marker for diagnosis of breast cancer
11/27/2002	EP1259604A1 Bcmp 84, a protein associated to breast cancer
11/27/2002	EP1259598A2 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
11/27/2002	EP1259563A2 Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
11/27/2002	EP1259562A1 Sterically hindered derivatives of water soluble polymers
11/27/2002	EP1259541A2 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
11/27/2002	EP1259490A2 Synthesis of epothilones, intermediates thereto and analogues thereof
11/27/2002	EP1259269A1 Agent for the treatment of wounds
11/27/2002	EP1259265A2 Nucleic acid formulations for gene delivery and methods of use
11/27/2002	EP1259264A2 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
11/27/2002	EP1259263A1 Complexation of rna, especially ribozymes, with polyethylenimines for the stabilization and cellular introduction thereof
11/27/2002	EP1259262A1 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
11/27/2002	EP1259261A1 Pharmaceutical compositions comprising terbinafine
11/27/2002	EP1259259A2 Mucosal adjuvant formulation
11/27/2002	EP1259256A1 Antigenic complexes and methods
11/27/2002	EP1259250A1 Endoparasiticidal agents
11/27/2002	EP1259244A1 Veterinary compositions for the treatment of parasitic diseases
11/27/2002	EP1259238A1 Stable acid labile benzimidazole pharmaceutical compositions
11/27/2002	EP1259230A2 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
11/27/2002	EP1259228A1 Therapeutic compositions for pulmonary delivery
11/27/2002	EP1259226A2 Anaesthetic formulations
11/27/2002	EP1259225A2 Liposomes
11/27/2002	EP1259224A2 Cochleate formulations and their use for delivering biologically relevant molecules
11/27/2002	EP1259223A1 Protein matrix materials, devices and methods of making and using thereof
11/27/2002	EP1259190A2 Method for making, loading and sealing a cell or drug encapsulation device, and such a device
11/27/2002	EP1259128A1 Water containing soluble fiber
11/27/2002	EP1259114A1 A topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
11/27/2002	EP1259112A1 Nutritional intervention composition for enhancing and extending satiety
11/27/2002	EP1107795B1 Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
11/27/2002	EP1059931B1 Utilization of cd137 in order to promote the proliferation of peripheral monocytes
11/27/2002	EP1028758A4 Methods for treating prostate tumors using radioactive compositions
11/27/2002	EP1028757A4 Radioactive embolizing compositions
11/27/2002	EP0994887B1 Modified glycosides, compositions comprised thereof and methods of use thereof
11/27/2002	EP0871649B1 Conjugates of a polypeptide and a biocompatible polymer
11/27/2002	EP0857064B1 Stabilised pharmaceutical preparations containing thyroid hormone
11/27/2002	EP0854707B1 Solid medicaments obtained by extrusion of an isomalt-containing polymer-active substance melt
11/27/2002	EP0814782B1 Pharmaceutical composition stabilized with a basic agent
11/27/2002	EP0706401B1 Drug delivery system
11/27/2002	CN1382153A 重组亚单位疫苗 Recombinant subunit vaccine
11/27/2002	CN1382061A Pharmaceutical compositions for oral and topical administration
11/27/2002	CN1382058A Method to enhance healing of sternum after sternotomy
11/27/2002	CN1382051A Injectable bupernorphine microparticle compositions and their use
11/27/2002	CN1382050A Oral formulations for anti-tumor compounds
11/27/2002	CN1382049A Method for stabilizing benzimidazole compounds
11/27/2002	CN1382048A Formulation of substituted benzimidazoles

1 ... 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 ... 1712